Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

BACKGROUND: A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in adults aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhiwei, Hu, Yaling, Xu, Miao, Chen, Zhen, Yang, Wanqi, Jiang, Zhiwei, Li, Minjie, Jin, Hui, Cui, Guoliang, Chen, Panpan, Wang, Lei, Zhao, Guoqing, Ding, Yuzhu, Zhao, Yuliang, Yin, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906628/
https://www.ncbi.nlm.nih.gov/pubmed/33548194
http://dx.doi.org/10.1016/S1473-3099(20)30987-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906628/
https://www.ncbi.nlm.nih.gov/pubmed/33548194
http://dx.doi.org/10.1016/S1473-3099(20)30987-7

Ejemplares similares